481 related articles for article (PubMed ID: 28499730)
1. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
[TBL] [Abstract][Full Text] [Related]
2. Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
Matsukawa Y; Ishida S; Majima T; Funahashi Y; Sassa N; Kato M; Yoshino Y; Gotoh M
Int J Urol; 2017 Jun; 24(6):454-459. PubMed ID: 28370376
[TBL] [Abstract][Full Text] [Related]
3. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
Matsukawa Y; Gotoh M; Kato M; Funahashi Y; Narita M; Mitsui K
Int J Urol; 2014 Aug; 21(8):826-30. PubMed ID: 24661225
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study.
Takeda M; Yokoyama O; Yoshida M; Nishizawa O; Hirata K; Nakaoka R; Takita Y; Murakami M
Int J Urol; 2017 Jul; 24(7):539-547. PubMed ID: 28556284
[TBL] [Abstract][Full Text] [Related]
5. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
[TBL] [Abstract][Full Text] [Related]
6. What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study.
Matsukawa Y; Kato M; Funahashi Y; Majima T; Yamamoto T; Gotoh M
Neurourol Urodyn; 2017 Sep; 36(7):1809-1815. PubMed ID: 28102554
[TBL] [Abstract][Full Text] [Related]
7. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
[TBL] [Abstract][Full Text] [Related]
8. Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta-analysis of urodynamic studies.
Fusco F; Creta M; De Nunzio C; Gacci M; Li Marzi V; Finazzi Agrò E
Neurourol Urodyn; 2018 Aug; 37(6):1865-1874. PubMed ID: 29603785
[TBL] [Abstract][Full Text] [Related]
9. Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study.
Ichihara K; Masumori N; Iwasawa A; Taguchi K; Yamaguchi Y; Nishimura M; Sasamura H; Suzuki N; Haga K; Miyao N; Hirose T
Int J Urol; 2018 Oct; 25(10):849-854. PubMed ID: 30066966
[TBL] [Abstract][Full Text] [Related]
10. Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study.
Matsukawa Y; Majima T; Matsuo K; Funahashi Y; Kato M; Yamamoto T; Gotoh M
Int J Urol; 2018 Mar; 25(3):246-250. PubMed ID: 29164680
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
[TBL] [Abstract][Full Text] [Related]
12. Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology.
Villa L; Capogrosso P; Capitanio U; Martini A; Briganti A; Salonia A; Montorsi F
Adv Ther; 2019 Jan; 36(1):1-18. PubMed ID: 30523608
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study.
Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Gotoh M
Neurourol Urodyn; 2017 Mar; 36(3):748-754. PubMed ID: 27060991
[TBL] [Abstract][Full Text] [Related]
15. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
Wada N; Kita M; Hashizume K; Matsumoto S; Kakizaki H
Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
[TBL] [Abstract][Full Text] [Related]
16. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?
Yamanishi T; Kaga K; Fuse M; Shibata C; Kamai T; Uchiyama T
Int J Urol; 2015 Dec; 22(12):1143-8. PubMed ID: 26310102
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
Ito H; Sano F; Ogawa T; Yao M
Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
[TBL] [Abstract][Full Text] [Related]
18. Change of Ultrasound Estimated Bladder Weight and Bladder Wall Thickness After Treatment of Bladder Outlet Obstruction With Dutasteride.
Lee HN; Lee YS; Han DH; Lee KS
Low Urin Tract Symptoms; 2017 May; 9(2):67-74. PubMed ID: 28394496
[TBL] [Abstract][Full Text] [Related]
19. Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study.
Fusco F; Creta M; Longo N; Persico F; Franco M; Mirone V
BMC Urol; 2018 Mar; 18(1):12. PubMed ID: 29502524
[TBL] [Abstract][Full Text] [Related]
20. α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
Roehrborn CG; Cruz F; Fusco F
Adv Ther; 2017 Jan; 33(12):2110-2121. PubMed ID: 27752927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
